Glioblastoma is among the most prevalent primary brain tumor, accounting for 15–20% of all intracranial tumors. The median survival time is only 15 months. Among these, glioblastoma is characterized by excessive proliferation, high invasion and high resistance to clinical treatment [
1‐
3]. The current standard treatment for glioblastoma patients involves radical surgical resection followed by adjuvant radiation and chemotherapy, numerous antineoplastic drugs such as Doxorubicin (Dox) and Temozolomide (TMZ), are widely used as in clinical treatment of glioblastoma [
4,
5]. However, glioblastoma is notorious for its chemoresistance to treatment, and despite many efforts have been made, the addition of Dox and TMZ against glioblastoma have largely failed. Recurrence after chemo- and radiotherapy is inevitable and eventually leads to high mortality in patients with glioblastoma [
6]. Tumor initiation, therapeutic resistance, and recurrence originate from cancer-initiating cells (CICs) [
7‐
9]. CICs display some stem cell markers and exhibit sustained self-renewal. Glioblastoma cells with stem characteristics have been isolated from glioblastoma tissues or established glioblastoma cell lines, based on the expression of stem cell markers and the ability to survive in certain stem cell circumstances. Glioblastoma-initiating cells have been found to exhibit resistance to chemotherapy and radiotherapy, tumor-initiating potential, migration, and proliferative capacity [
10].
Generally, the concepts of how CICs gain their ability to self-renew and proliferate are hardly understood. In the past decade, Takahashi [
11] found that cancer cells could gain the embryonic characteristics enabling self-renew, which might be comparable to the reprogramming of differentiated somatic cells to induced pluripotent stem cells (iPSCs) by introducing embryonic stem cell transcription factors. Meanwhile, cancers acquire characteristic properties by reactivating genes normally expressed in embryonic and fetal life. The description of cancer-embryonic genes like CEA, the anomalous production of human chorionic gonadotrophin by a range of histologically distinct cancers, and the finding that germline genes are involved in the process of invasion and metastases [
12,
13]. Previous work focusing on germline traits in cancers led to the discovery of cancer-germline (CG) genes, also called cancer-testis (CT) genes, which are mainly expressed in germline cells and are barely expressed in somatic adult tissues; however, they are abnormally activated in a wide variety of tumors [
14]. Some of these human CG genes are suspected to be involved in the germline traits of oncogenesis, such as invasiveness, metastasis, immortality, angiogenesis, and hypomethylation, so they are being studied as biomarkers for cancers [
14]. Dazl (
Deleted in
azoospermia-like), a member of the DAZ (
Deleted in
Azoospermia) gene family, which is also identified as a marker for germ cell identification [
15]. Dazl is conserved in all vertebrates and acts as a meiosis-promoting factor in developing germ cells [
16]. It is also a “licensing factor” that is required for primordial germ cells (PGCs) sexual differentiation [
17]. Dazl can directly regulate apoptosis in PGCs by suppressing the translation of Caspase RNAs, loss of Dazl expression results in apoptosis of the postmigratory germ cells and infertility in both sexes in mice, with germ cell loss during development and a final block at meiosis [
18,
19]. During the transition of PGCs into germ cells, Dazl acts as a translational regulator and regulates the transcription of the stemness genes
Sox2,
Sall4, and
Suz12 [
15,
20]. Sox2 regulates proliferation, migration, invasion, and colony formation of glioblastoma cells [
21,
22]. CD133, Oct4, and Nanog are identified as stem/progenitor cell markers of glioblastoma [
10] and participate in the tumorigenesis of astrocytic glioblastoma [
22‐
25]. Moreover, Dazl identified as a novel cancer germline gene and could promote the proliferation and resistance to chemical drugs of lung cancer cells by enhancing the translation of RRM2 [
26]. However, whether Dazl is involved in the formation of glioblastoma has not been reported. Herein, to explore the correlation of Dazl expression and the tumorigenesis of glioblastoma, we generated glioblastoma Dazl
+/− GBM cell lines using the CRISPR/Cas9 gene editing system, and we evaluated that the Dazl knockdown attenuated cell proliferation, reduced cell migration, invasion, and chemo-resistance. These results support the concept that Dazl may be a cancer-germline gene involved in the development of human glioblastoma cells.